TA Associates, a global growth private equity firm, has completed a strategic growth investment in Synokem Pharmaceuticals Ltd.
 
Founded in 1983 by Mr. J.M. Arora, Synokem Pharmaceuticals Ltd. is one of India’s leading contract development and manufacturing organizations (CDMOs), serving customers in the branded generic domestic formulations market. In addition, the company’s products are exported to more than 30 countries. Synokem is based in New Delhi, India, with manufacturing and R&D facilities in Haridwar, India.
 
Synokem’s founders will continue as shareholders in the Company alongside TA.
 
“We have been consistently impressed both by Synokem’s commitment to innovation and its excellent and enduring relationship with customers,” said Dhiraj Poddar, managing director and head of Indian operations for TA Associates Advisory Pvt. Ltd. “That the company has delivered numerous first-to-market products is further indicative of its industry-leading position. We believe Synokem can serve as a high-quality producer of pharma products, not just for India but also for international markets. We are excited to partner with Synokem’s management team to drive growth, including through strategic acquisitions.”
 
“With industry expansion being driven by both demographic and economic factors, including higher health insurance penetration and affordability, we believe there is a strong opportunity to build on Synokem’s momentum and further expand its capabilities,” added Vishal Gupta, director at TA. “We look forward to complementing the organic growth of the Company with TA’s expertise in strategic acquisitions, as well as our broad network and global resources.”
 
“We believe TA is an ideal partner for Synokem as we enter the next phase of our journey,” said Abhinav Arora, managing director of Synokem. “The firm’s deep industry knowledge and experience scaling companies like ours will meaningfully boost our ability to pursue both organic and inorganic growth, thereby increasing our market share and further positioning Synokem as an industry leader.”
 
Financial terms of the transaction were not disclosed.